Summary
The single-dose pharmacokinetics of indomethacin following 100 mg rectally was measured in two groups of 8 healthy subjects before and after diflunisal 500 mg p.o. once daily, or 500 mg in the morning and 1000 mg in the evening, until steady state conditions were reached. A further group of 8 healthy subjects was given 50 mg indomethacin rectally before and after diflunisal 500 mg p.o. twice daily.
High dose diflunisal (1500 mg/day) decreased the renal clearance of indomethacin from 21.9 to 1.8 ml/min (92%) and reduced the renal excretion of both unchanged (63%) and conjugated (82%) indomethacin. The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%. The maximum plasma concentration (2.4 µg/ml) and total area under the curve (13.0 µg × h/ml) were increased by 40% and 119%, respectively. The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal. The contribution of metabolism to the overall elimination of indomethacin was increased by only 2%.
Similar results were obtained when the subjects were challenged with the low dose of diflunisal (500 mg/day), although the magnitude of the changes were smaller. The interaction between indomethacin and diflunisal may be due to competition both at the metabolic (conjugation) and the excretory (tubular secretion) levels.
When the subjects were given 50 mg indomethacin and diflunisal 1000 mg/day simultaneously, the achieved maximum plasma concentration of indomethacin (2.53 µg/ml) was comparable to that seen after 100 mg in the absence of diflunisal (3.1 µg/ml), but the AUC was greater (21.7 µg × h/ml vs 13.0 µg × h/ml).
Adverse central nervous reactions were more frequent and more pronounced at higher plasma indomethacin concentrations.
Similar content being viewed by others
References
Day RO, Graham GG, Champion GD, Lee E (1984) Antirheumatic drug interactions. Clin Rheum Dis 10: 251–275
Helleberg L (1981) Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 6: 245–258
Verbeeck RK, Blackburn JL, Loewen GR (1983) Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8: 297–331
Webster J (1985) Interactions of NSAIDs with diuretics and beta-blockers. Mechanism and Clinical Implications. Drugs 30: 32–41
Kwan KC, Breault GO, Davos RL, Lei BW, Czerwinski AW, Besselaar GH, Duggan DE (1978) Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. J Pharmacokinet Biopharm 6: 451–475
Rubin A, Rodda BE, Warrick P, Gruber CM, Ridolfo AS (1973) Interactions of aspirin with non-steroidal anti-inflammatory drugs in man. Arthritis Rheum 16: 635–645
Ragheb M, Ban Ta, Buchanan D, Frölich JC (1980) Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiat 41: 397–398
Reimann IW, Diener U, Frölich JC (1983) Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry 40: 283–286
Van Dusen J, Fischl SJ (1981) Inhibition of nitroglycerin effect in humans by suppression of prostaglandin E. Am J Cardiol 47: 390
Liegler DG, Henderson ES, Hahn MA, Oliverio VT (1969) The effect of organic acids on the renal clearance of methotrexate in man. Clin Pharmacol Ther 10: 849–857
Turner RA, Whipple JP, Shackleford RW (1984) Diflunisal 500–750 mg versus aspirin 2600–3900 mg in the treatment of rheumatoid arthritis. Pharmacotherapy 4: 151–157
Fischel B, Weiss S, Yavon M (1981) Diflunisal in rheumatoid arthritis. Inflammation 5: 253–261
De Schepper PJ, Tjandramaga TB, De Roo M, Verhaest L, Daurio C, Steelman SL, Tempero KF (1978) Gastrointestinal blood loss after diflunisal and after aspirin: Effect of aspirin. Clin Pharmacol Ther 23: 669–676
Tringham VM, Cochrane P (1979) Aspirin, paracetamol, diflunisal and gastrointestinal blood loss. Lancet 1: 1409
Lindholm L, Ekdahl C, Håkansson E, Melander A, Olsson S, Svensson B, Wåhlin-Boll E (1981) Comparison of diflunisal and acetylsalicylic acid in patients with rheumatoid arthritis. Scand J Rheumatol 10: 289–295
De Silva M, Hazleman BL, Dippy JE (1980) Diflunisal and aspirin: A comparative study in rheumatoid arthritis. Rheumatol Rehabil 19: 126–130
Caruso I, Biancho Porro G (1980) Gastroscopic evaluation of anti-inflammatory agents. Br Med J 280: 75–78
Tocco DJ, Brault GO, Zacchei AG, Steelman SL, Perrier CV (1975) Physiological disposition and metabolism of 5-(2′,4′-difluorophenyl) salicylic acid, a new salicylate. Drug Metab Dispos 3: 453–466
Hvidberg E, Lausen HH, Jansen JA (1972) Indomethacin: Plasma concentrations and protein binding in man. Eur J Clin Pharmacol 4: 119–124
Duggan DE, Hogans AF, Kwan KC, McMahon FG (1972) The metabolism of indomethacin in man. J Pharmacol Exp Ther 181: 563–575
Kwan KC, Breault GO, Umbenhauer ER, McMahon RG, Duggan DE (1976) The kinetics of indomethacin: Absorption, elimination and enterohepatic circulation in man. J Pharmacokinet Biopharm 4: 255–280
Skeith MD, Simkin PA, Healey LA (1968) The renal excretion of indomethacin and its inhibition by probenecid. Clin Pharmacol Ther 9: 89–93
Baber N, Halliday L, Sibeon R, Littler T, Orme ML (1978) The interaction between indomethacin and probenecid: A clinical and pharmacokinetic study. Clin Pharmacol Ther 24: 298–306
Baer JE, Breault GO, Russo HF (1978) Diflunisal renal clearance in anesthetized dogs — effect of probenecid, urine flow and pH. Arch Int Pharmacodyn Ther 235: 204–210
Dresse A, Gerard MA, Quinaux N, Fischer P, Gerardy J (1978) Effect of diflunisal on the human plasma levels and on the urinary excretion of naproxen. Arch Int Pharmacodyn Ther 236: 276–284
Van Hecken AM, Tjandramaga TB, Verbesselt R, De Schepper PJ (1985) The influence of diflunisal on the pharmacokinetics of oxazepam. Br J Clin Pharmacol 20: 225–234
Pacifici GM, Rane A (1981) Inhibition of morphine glucuronidation by oxazepam in human fetal liver microsomes. Drug Metabol Disposit 9: 569–572
Säwe J, Pacifici GM, Kager L, von Bahr C, Rane A (1982) Glucuronidation of morphine in human liver and interaction with oxazepam. Acta Anaesth Scand Suppl 74: 47–51
Dybing E (1976) Inhibition of acetaminophen glucuronidation by oxazepam. Biochem Pharmacol 25: 1421–1425
Faed EM, Dobbs BR, Lee D (1984) Glucuronidation and elimination of diflunisal in the isolated perfused rat liver. Effect of pretreatment with phenobarbitone, clofibric-acid and spironolactone. Arch Int Pharmacodyn Ther 272: 4–16
Levy G, Procknal JA (1968) Drug biotransformation interactions in man. Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man. J Pharm Sci 57: 1330–1335
Miners JO, Grugurinovich N, Whitehead AG, Robson RA, Birkett DJ (1986) Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol 22: 135–142
Patwardhan R, Mitchell MC, Johnson R, Schenker S (1981) Induction of glucuronidation by oral contraceptive steroids. Clin Res 29: 861A
Miners JO, Robson RA, Birkett DJ (1984) Gender and oral contraceptive steroids as determinants of glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol 18: 240–243
Mitchell MC, Hanew T, Meredith CG, Schenker S (1983) Effects of oral contraceptive steroids on acetominophen metabolism and elimination. Clin Pharmacol Ther 34: 48–53
Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB (1984) Effect of oral contraceptives on triazolam, temazepam, alprazolam and lorazepam kinetics. Clin Pharmacol Ther 36: 683–690
Wåhlin-Boll E, Brantmark B, Hansson A, Melander A, Nilsson C (1981) High pressure liquid chromatographic determination of acetylsalicylic acid, salicylic acid, diflunisal, indomethacin, indoprofen and indobufen. Eur J Clin Pharmacol 20: 375–378
Lott RS, Hayton WL (1978) Estimation of creatinine clearance from serum creatinine concentration. Drug Intell Clin Pharmacol 12: 140–150
Dutton GJ (1966) Glucuronic acid. Academic Press, New York and London, p 186
Brooks PM, Bell MA, Lee P, et al. (1974) The effect of furosemide on indomethacin plasma levels. Br J Clin Pharmacol 1: 485–489
Brooks PM, Bell MA, Walker JJ, Kennedy AC, Sturrock RD, Dich WC (1975) Ups and downs of indomethacin bioavailability. Ann Rheum Dis 34: 465–466
Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E (1978) Naproxen-Probenecid interaction. Clin Pharm Ther 24: 706–713
Yü TF, Perel J (1980) Pharmacokinetic and clinical studies of carprofen in gout. J Clin Pharmacol 20: 347–351
Meffin PJ, Zilm DM, Veenedahl JR (1983) A renal mechanism for the clofibric acid-probenecid interaction. J Pharmacol Exp Ther 227: 739–742
Hart DF (1982) Indomethacin. In: Drug treatment of the rheumatic diseases, 2nd edn. Adis Press, p 26–30
Alvan G, Orme M, Bertillson L, Ekstrand R, Palmer L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18: 364–373
Rothermich NO (1966) An extended study of indomethacin. Clinical pharmacology. J Am Med Assoc 195: 123–128
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eriksson, L.O., Wåhlin-Boll, E., Liedholm, H. et al. Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. Eur J Clin Pharmacol 37, 7–15 (1989). https://doi.org/10.1007/BF00609416
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609416